PF-55693 |
LETRAM 500 mg/ 5 mL Solución inyectable |
2023-08-21 |
|
Aspiro Pharma Limited |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-55821 |
OMZENIX 40 mg Polvo liofilizado para uso parenteral |
2023-09-19 |
|
Aspiro Pharma Limited |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56880 |
VANCOMICINA CLORHIDRATO Aspiro 500 mg Polvo Liofilizado para Uso Parenteral |
2024-07-02 |
|
Aspiro Pharma Limited |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56885 |
VANCOMICINA CLORHIDRATO Aspiro 1 g Polvo Liofilizado para Uso Parenteral |
2024-07-03 |
|
Aspiro Pharma Limited |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56909 |
PROPONEX 10 mg / mL Emulsión Inyectable |
2024-07-08 |
|
Aspiro Pharma Limited |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-57352 |
VORICA 200 mg Polvo liofilizado para uso parenteral |
2024-10-22 |
|
Aspiro Pharma Limited |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-57538 |
KETOROLACO TROMETAMOL Aspiro 15 mg/mL Solución Inyectable |
2024-11-25 |
|
Seven Pharma Chile, S.p.A. |
India
|
Seven Pharma Guatemala |
Alpha Pharma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-58711 |
KETOROLACO TROMETAMOL Aspiro 30 mg/mL Solución Inyectable |
2025-10-27 |
|
Seven Pharma Chile, S.p.A. |
India
|
Seven Pharma Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-42563 |
PROGRAF XL 0.5 mg cápsulas de liberación prolongada |
2029-04-12 |
|
Astellas Pharma US, Inc. |
Irlanda
|
J.I.Cohen, S.A. |
Agencias J. I. Cohen |
Asofarma |
Centro Distribuidor, Sociedad Anónima |
Droguería Y Farmacia Lanquetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-42590 |
PROGRAF XL 1 mg Cápsulas de liberación prolongada |
2029-04-16 |
|
Astellas Pharma US, Inc. |
Irlanda
|
J.I.Cohen, S.A. |
Agencias J. I. Cohen |
Asofarma |
Centro Distribuidor, Sociedad Anónima |
Droguería Y Farmacia Lanquetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|